Issues involving international trade, including IP protections
Issues related to corporate tax reform
Issues related to Medicare Part D, including program restructuring, coverage gap, rebate reform, and out-of-pocket costs
Issues related to drug pricing, value, and transparency, generally
International Reference Pricing/Most Favored Nations
Issues related to drug pricing, value, and transparency, generally
Issues related to biosimilars, generally
Rebate reform, patient out-of-pocket costs, and value-based payment arrangements, generally
Drug importation
Drug shortages
Issues related to vaccines, generally
Duration: January 31, 2014
to
present
General Issues: Trade (Domestic & Foreign) , Taxation/Internal Revenue Code , Medicare/Medicaid , Health Issues , Copyright/Patent/Trademark
Spending: about $2,580,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2014: U.S. Senate, House of Representatives
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Steven Irizarry Counsel, Senate HELP
Counsel, House Energy and Commerce
Counsel, Senate Aging Committee
Staffer, Sen. Chuck Hagel
Israel Klein Deputy Staff Director, Joint Economic Committee, Chairman Chuck Schumer Senior Communications Advisor, Rep. Ed Markey Communications Director, Sen. Chuck Schumer Press Secretary and Legislative Assistant, Rep. Ed Markey
Lydia Strunk Deputy Floor Director Speaker Ryan (2015-17); Deputy Floor Director Speaker Boehner (2013-15); House Rules Committee 2011-13; House Republican Cloakroom Floor Assistant 2008-2011 (Minority Leader Boehner/Speaker Boehner)
Vincent Roberti Sr. n/a
Vincent Roberti Sr n/a
Vincent Roberti n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, Roberti Global (fka Roberti White, LLC) did no lobbying for Pfizer Inc. . The report was filed on April 21.
Original Filing: 301569326.xml
4th Quarter, 2023
In Q4, Roberti Global (fka Roberti White, LLC) did no lobbying for Pfizer Inc. . The report was filed on Jan. 21.
Original Filing: 301534954.xml
3rd Quarter, 2023
In Q3, Roberti Global (fka Roberti White, LLC) did no lobbying for Pfizer Inc. . The report was filed on Oct. 18, 2023.
Original Filing: 301505045.xml
2nd Quarter, 2023
In Q2, Roberti Global (fka Roberti White, LLC) did no lobbying for Pfizer Inc. . The report was filed on July 18, 2023.
Original Filing: 301478886.xml
1st Quarter, 2023
In Q1, Roberti Global (fka Roberti White, LLC) did no lobbying for Pfizer Inc. . The report was filed on April 20, 2023.
Original Filing: 301461563.xml
4th Quarter, 2022
In Q4, Roberti Global (fka Roberti White, LLC) did no lobbying for Pfizer Inc. . The report was filed on Jan. 18, 2023.
Original Filing: 301430375.xml
3rd Quarter, 2022
In Q3, Roberti Global (fka Roberti White, LLC) did no lobbying for Pfizer Inc. . The report was filed on Oct. 20, 2022.
Original Filing: 301415646.xml
2nd Quarter, 2022
In Q2, Roberti Global (fka Roberti White, LLC) lobbied for Pfizer Inc. , earning $60,000. The report was filed on July 19, 2022.
Original Filing: 301387213.xml
Lobbying Issues
Issues involving international trade, including IP protections
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to corporate tax reform
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Medicare Part D, including program restructuring, coverage gap, rebate reform, and out-of-pocket costs
Issues related to drug pricing, value, and transparency, generally
International Reference Pricing/Most Favored Nations
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to drug pricing, value, and transparency, generally
Issues related to biosimilars, generally
Rebate reform, patient out-of-pocket costs, and value-based payment arrangements, generally
Drug importation
Drug shortages
Issues related to vaccines, generally
Agencies Lobbied
U.S. Senate
1st Quarter, 2022
In Q1, Roberti Global (fka Roberti White, LLC) lobbied for Pfizer Inc. , earning $60,000. The report was filed on April 18, 2022.
Original Filing: 301359300.xml
Lobbying Issues
Issues involving international trade, including IP protections
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to corporate tax reform
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Medicare Part D, including program restructuring, coverage gap, rebate reform, and out-of-pocket costs
Issues related to drug pricing, value, and transparency, generally
International Reference Pricing/Most Favored Nations
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to drug pricing, value, and transparency, generally
Issues related to biosimilars, generally
Rebate reform, patient out-of-pocket costs, and value-based payment arrangements, generally
Drug importation
Drug shortages
Issues related to vaccines, generally
Agencies Lobbied
U.S. Senate
4th Quarter, 2021
In Q4, Roberti Global (fka Roberti White, LLC) lobbied for Pfizer Inc. , earning $60,000. The report was filed on Jan. 20, 2022.
Original Filing: 301331753.xml
Lobbying Issues
Issues involving international trade, including IP protections
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to corporate tax reform
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Medicare Part D, including program restructuring, coverage gap, rebate reform, and out-of-pocket costs
Issues related to drug pricing, value, and transparency, generally
International Reference Pricing/Most Favored Nations
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to drug pricing, value, and transparency, generally
Issues related to biosimilars, generally
Rebate reform, patient out-of-pocket costs, and value-based payment arrangements, generally
Drug importation
Drug shortages
Issues related to vaccines, generally
Agencies Lobbied
U.S. Senate
3rd Quarter, 2021
In Q3, Roberti Global (fka Roberti White, LLC) lobbied for Pfizer Inc. , earning $60,000. The report was filed on Oct. 19, 2021.
Original Filing: 301305975.xml
Lobbying Issues
Issues involving international trade, including IP protections
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to corporate tax reform
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Medicare Part D, including program restructuring, coverage gap, rebate reform, and out-of-pocket costs
Issues related to drug pricing, value, and transparency, generally
International Reference Pricing/Most Favored Nations
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to drug pricing, value, and transparency, generally
Issues related to biosimilars, generally
Rebate reform, patient out-of-pocket costs, and value-based payment arrangements, generally
Drug importation
Drug shortages
Issues related to vaccines, generally
Agencies Lobbied
U.S. Senate
2nd Quarter, 2021
In Q2, Roberti Global (fka Roberti White, LLC) lobbied for Pfizer Inc. , earning $60,000. The report was filed on July 20, 2021.
Original Filing: 301289540.xml
Lobbying Issues
Issues involving international trade, including IP protections
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to corporate tax reform
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Medicare Part D, including program restructuring, coverage gap, rebate reform, and out-of-pocket costs
Issues related to drug pricing, value, and transparency, generally
International Reference Pricing/Most Favored Nations
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to drug pricing, value, and transparency, generally
Issues related to biosimilars, generally
Rebate reform, patient out-of-pocket costs, and value-based payment arrangements, generally
Drug importation
Drug shortages
Issues related to vaccines, generally
Agencies Lobbied
U.S. Senate
1st Quarter, 2021
In Q1, Roberti Global (fka Roberti White, LLC) lobbied for Pfizer Inc. , earning $60,000. The report was filed on April 19, 2021.
Original Filing: 301258261.xml
Lobbying Issues
Issues involving international trade, including IP protections
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to corporate tax reform
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Medicare Part D, including program restructuring, coverage gap, rebate reform, and out-of-pocket costs
Issues related to drug pricing, value, and transparency, generally
International Reference Pricing/Most Favored Nations
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to drug pricing, value, and transparency, generally
Issues related to biosimilars, generally
Rebate reform, patient out-of-pocket costs, and value-based payment arrangements, generally
Drug importation
Drug shortages
Issues related to vaccines, generally
Agencies Lobbied
U.S. Senate
4th Quarter, 2020
In Q4, Roberti Global (fka Roberti White, LLC) lobbied for Pfizer Inc. , earning $80,000. The report was filed on Jan. 20, 2021.
Original Filing: 301239433.xml
Lobbying Issues
Issues involving international trade, including IP protections
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
- Issues related to international tax reform
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Medicare Part B, generally
Issues related to Medicare Part D, including program restructuring, rebate reform, and beneficiary out-of-pocket costs
Value-based payment arrangements
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare Part B, generally
Issues related to Medicare Part D, including program restructuring, rebate reform, and beneficiary out-of-pocket costs
Value-based payment arrangements
Issues related to drug pricing, value, and transparency, generally
Issues related to biosimilars, generally
Rebate reform, patient out-of-pocket costs, and value-based payment arrangements, generally.
Drug shortages
Agencies Lobbied
U.S. Senate
3rd Quarter, 2020
In Q3, Roberti Global (fka Roberti White, LLC) lobbied for Pfizer Inc. , earning $80,000. The report was filed on Oct. 19, 2020.
Original Filing: 301214503.xml
Lobbying Issues
Issues involving international trade, including IP protections
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
- Issues related to international tax reform
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Medicare Part B, generally
Issues related to Medicare Part D, including program restructuring, rebate reform, and beneficiary out-of-pocket costs
Value-based payment arrangements
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to drug shortages, generally
Issues related to drug pricing and value, and transparency, generally, including the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
Rebate reform, patient out-of-pocket costs, and value-based payment arrangements, generally.
Drug shortages.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2020
In Q2, Roberti Global (fka Roberti White, LLC) lobbied for Pfizer Inc. , earning $80,000. The report was filed on July 20, 2020.
Original Filing: 301201255.xml
Lobbying Issues
Issues involving international trade, including IP protections
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
- Issues related to international tax reform
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Medicare Part B, generally
Issues related to Medicare Part D, including program restructuring, rebate reform, and beneficiary out-of-pocket costs
Value-based payment arrangements
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to drug shortages, generally
Issues related to drug pricing and value, and transparency, generally, including the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
Rebate reform, patient out-of-pocket costs, and value-based payment arrangements, generally.
Drug shortages.
Agencies Lobbied
U.S. Senate
1st Quarter, 2020
In Q1, Roberti Global (fka Roberti White, LLC) lobbied for Pfizer Inc. , earning $80,000. The report was filed on April 20, 2020.
Original Filing: 301175512.xml
Lobbying Issues
Issues involving international trade, including IP protections
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
- Issues related to international tax reform
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Medicare Part B, generally
Issues related to Medicare Part D, including program restructuring, rebate reform, and beneficiary out-of-pocket costs
Value-based payment arrangements
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to drug shortages, generally
Issues related to drug pricing and value, and transparency, generally, including the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
Rebate reform, patient out-of-pocket costs, and value-based payment arrangements, generally.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (S. 340/H.R. 965)
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2019
Roberti Global (fka Roberti White, LLC) amended a lobbying report for representation of Pfizer Inc. in Q42019 on Jan. 22, 2020.
Original Filing: 301129791.xml
Lobbying Issues
Issues involving international trade, including IP protections
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
- Issues related to international tax reform
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Medicare Part B, generally
Issues related to Medicare Part D, including program restructuring, rebate reform, and beneficiary out-of-pocket costs
Value-based payment arrangements
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to drug pricing and value, and transparency, generally, including the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
Issues related to biosimilars, generally
Rebate reform, patient out-of-pocket costs, and value-based payment arrangements, generally.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (S. 340/H.R. 965)
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2019
In Q4, Roberti Global (fka Roberti White, LLC) lobbied for Pfizer Inc. , earning $80,000. The report was filed on Jan. 21, 2020.
Original Filing: 301124794.xml
Lobbying Issues
Issues involving international trade, including IP protections
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
- Issues related to international tax reform
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Medicare Part B, generally
Issues related to Medicare Part D, including program restructuring, rebate reform, and beneficiary out-of-pocket costs
Value-based payment arrangements
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to drug pricing and value, and transparency, generally, including the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
Issues related to biosimilars, generally
Rebate reform, patient out-of-pocket costs, and value-based payment arrangements, generally.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (S. 340/H.R. 965)
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2019
Roberti Global (fka Roberti White, LLC) amended a lobbying report for representation of Pfizer Inc. in Q32019 on Jan. 22, 2020.
Original Filing: 301129792.xml
Lobbying Issues
Issues involving international trade, including IP protections
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
- Issues related to international tax reform
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Medicare Part B, generally
Issues related to Medicare Part D, including program restructuring, rebate reform, and beneficiary out-of-pocket costs
Value-based payment arrangements
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to drug pricing and value, generally, including the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
Issues related to biosimilars, generally
Rebate reform, patient out-of-pocket costs, and value-based payment arrangements, generally.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (S. 340/H.R. 965)
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2019
In Q3, Roberti Global (fka Roberti White, LLC) lobbied for Pfizer Inc. , earning $80,000. The report was filed on Oct. 21, 2019.
Original Filing: 301078267.xml
Lobbying Issues
Issues involving international trade, including IP protections
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
- Issues related to international tax reform
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Medicare Part B, generally
Issues related to Medicare Part D, including program restructuring, rebate reform, and beneficiary out-of-pocket costs
Value-based payment arrangements
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to drug pricing and value, generally, including the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
Issues related to biosimilars, generally
Rebate reform, patient out-of-pocket costs, and value-based payment arrangements, generally.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (S. 340/H.R. 965)
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2019
In Q2, Roberti Global (fka Roberti White, LLC) lobbied for Pfizer Inc. , earning $80,000. The report was filed on July 22, 2019.
Original Filing: 301056232.xml
Lobbying Issues
Issues involving international trade, including IP protections
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
- Issues related to international tax reform
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to Medicare Part B, generally
Issues related to Medicare Part D, including program restructuring, rebate reform, and beneficiary out-of-pocket costs
Value-based payment arrangements
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to drug pricing and value, generally, including the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
Issues related to biosimilars, generally
Rebate reform, patient out-of-pocket costs, and value-based payment arrangements, generally.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (S. 340/H.R. 965)
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2019
In Q1, Roberti Global (fka Roberti White, LLC) lobbied for Pfizer Inc. , earning $80,000. The report was filed on May 6, 2019.
Original Filing: 301040284.xml
Lobbying Issues
- Issues involving international trade
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
- Issues related to international tax reform
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
-Issues related to Medicare Part B, generally
-Issues related to Medicare Part D, generally; Bipartisan Budget Act (H.R. 1892); Consolidated Appropriations Act (H.R. 1625)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the importation of prescription medicines, generally
Antibiotic resistance; Pandemic All Hazards Preparedness Act (PAHPA) reauthorization
Issues related to drug pricing and value, generally, including the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
Reimbursement for products treating Sickle Cell Disease
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (S. 974/H.R. 2212)
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2018
In Q4, Roberti Global (fka Roberti White, LLC) lobbied for Pfizer Inc. , earning $80,000. The report was filed on Jan. 22, 2019.
Original Filing: 301016236.xml
Lobbying Issues
- Issues involving international trade
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
- Issues related to international tax reform
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
-Issues related to Medicare Part B, generally
- Issues related to Medicare Part D, generally; Bipartisan Budget Act (H.R. 1892); Consolidated Appropriations Act (H.R. 1625)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the importation of prescription medicines, generally
Antibiotic resistance; Pandemic All Hazards Preparedness Act (PAHPA) reauthorization
Issues related to drug pricing and value, generally, including the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
Reimbursement for products treating Sickle Cell Disease
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (S. 974/H.R. 2212)
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2018
In Q3, Roberti Global (fka Roberti White, LLC) lobbied for Pfizer Inc. , earning $80,000. The report was filed on Oct. 22, 2018.
Original Filing: 300997839.xml
Lobbying Issues
- Issues involving international trade
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
- Issues related to international tax reform
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
-Issues related to Medicare Part B, generally
- Issues related to Medicare Part D, generally; Bipartisan Budget Act (H.R. 1892); Consolidated Appropriations Act (H.R. 1625)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the importation of prescription medicines, generally
Antibiotic resistance; Pandemic All Hazards Preparedness Act (PAHPA) reauthorization
Issues related to drug pricing and value, generally, including the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
Reimbursement for products treating Sickle Cell Disease
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (S. 974/H.R. 2212)
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2018
In Q2, Roberti Global (fka Roberti White, LLC) lobbied for Pfizer Inc. , earning $80,000. The report was filed on July 20, 2018.
Original Filing: 300977137.xml
Lobbying Issues
- Issues involving international trade
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
- Issues related to international tax reform
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
-Issues related to Medicare Part B, generally
- Issues related to Medicare Part D, generally; Bipartisan Budget Act (H.R. 1892); Consolidated Appropriations Act (H.R. 1625)
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Issues related to the importation of prescription medicines; Affordable and Safe Prescription Drug Importation Act (H.R. 1245/S. 469)
- Antibiotic resistance; Pandemic All Hazards Preparedness Act (PAHPA) reauthorization
- Issues related to drug pricing and value, generally
- Reimbursement for products treating Sickle Cell Disease
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (S. 974/H.R. 2212)
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2018
In Q1, Roberti Global (fka Roberti White, LLC) lobbied for Pfizer Inc. , earning $80,000. The report was filed on April 20, 2018.
Original Filing: 300956994.xml
Lobbying Issues
- Issues involving international trade
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
- Issues related to international tax reform
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
-Issues related to Medicare Part B, generally
- Issues related to Medicare Part D, generally; Bipartisan Budget Act (H.R. 1892); Consolidated Appropriations Act (H.R. 1625)
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Issues related to the importation of prescription medicines; Affordable and Safe Prescription Drug Importation Act (H.R. 1245/S. 469)
- Antibiotic resistance; Pandemic All Hazards Preparedness Act (PAHPA) reauthorization
- Issues related to drug pricing and value, generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (S. 974/H.R. 2212)
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2017
In Q4, Roberti Global (fka Roberti White, LLC) lobbied for Pfizer Inc. , earning $80,000. The report was filed on Jan. 22, 2018.
Original Filing: 300933237.xml
Lobbying Issues
- Issue on international trade
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
- Issues related to international tax reform
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
- Issues related to Medicare Part D
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Prescription opioid-related issues
- Issues related to the importation of prescription medicines, including the Affordable and Safe Prescription Drug Importation Act (H.R. 1245/S. 469)
- Legislation repealing and replacing the Affordable Care Act, including the American Health Care Act (H.R. 1628)
- Issues related to drug pricing, including the Improving Access to Affordable Prescription Drugs Act (S. 771)
- Issues involving the Federal, Food, Drug and Cosmetic Act (FFDCA)
Agencies Lobbied
U.S. Senate
3rd Quarter, 2017
In Q3, Roberti Global (fka Roberti White, LLC) lobbied for Pfizer Inc. , earning $80,000. The report was filed on Oct. 20, 2017.
Original Filing: 300914832.xml
Lobbying Issues
- Issue on international trade
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
- Issues related to international tax reform
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
- Issues related to Medicare Part D
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Prescription opioid-related issues
- Issues related to the importation of prescription medicines, including the Affordable and Safe Prescription Drug Importation Act (H.R. 1245/S. 469)
- Legislation repealing and replacing the Affordable Care Act, including the American Health Care Act (H.R. 1628)
- Issues related to drug pricing, including the Improving Access to Affordable Prescription Drugs Act (S. 771)
- Issues involving the Federal, Food, Drug and Cosmetic Act (FFDCA), including reauthorization of the Prescription Drug User Fee Act (PDUFA VI)
Agencies Lobbied
U.S. Senate
2nd Quarter, 2017
In Q2, Roberti Global (fka Roberti White, LLC) lobbied for Pfizer Inc. , earning $80,000. The report was filed on July 20, 2017.
Original Filing: 300894615.xml
Lobbying Issues
- Issue on international trade
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
- Issues related to international tax reform
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
- Issues related to Medicare Part D
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Prescription opioid-related issues
- Issues related to the importation of prescription medicines, including the Affordable and Safe Prescription Drug Importation Act (H.R. 1245/S. 469)
- Legislation repealing and replacing the Affordable Care Act, including the American Health Care Act (H.R. 1628)
- Issues related to drug pricing, including the Improving Access to Affordable Prescription Drugs Act (S. 771)
- Issues involving the Federal, Food, Drug and Cosmetic Act (FFDCA), including reauthorization of the Prescription Drug User Fee Act (PDUFA VI)
Agencies Lobbied
U.S. Senate
1st Quarter, 2017
In Q1, Roberti Global (fka Roberti White, LLC) lobbied for Pfizer Inc. , earning $80,000. The report was filed on April 20, 2017.
Original Filing: 300876853.xml
Lobbying Issues
- Issue on international trade
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
- Issues related to international tax reform
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
- Issues related to Medicare Part D
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Prescription opioid-related issues
- Issues related to the importation of prescription medicines, including the Affordable and Safe Prescription Drug Importation Act (H.R. 1245/S. 469)
- Legislation repealing and replacing the Affordable Care Act, including the American Health Care Act (H.R. 1628)
- Issues related to drug pricing, including the Improving Access to Affordable Prescription Drugs Act (S. 771)
- Issues involving the Federal, Food, Drug and Cosmetic Act (FFDCA), including reauthorization of the Prescription Drug User Fee Act (PDUFA VI)
Agencies Lobbied
U.S. Senate
4th Quarter, 2016
In Q4, Roberti Global (fka Roberti White, LLC) lobbied for Pfizer Inc. , earning $80,000. The report was filed on Jan. 23, 2017.
Original Filing: 300856418.xml
Lobbying Issues
- Issue on international trade
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
- Issues related to international tax reform and inversions
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
- Medicare Rebates
- Medicare Part D
- CMMI Part B Drug Price Demonstration Program
- Non-Interference
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Prescription opioid-related issues
- Federal, Food, Drug, and Cosmetic Act
- Patient Protection and Affordable Care Act implementation
- 21st Century Cures Act (H.R. 6)
- Innovation for Healthier Americans (Senate)
- Part B drug payment demonstration rule
Agencies Lobbied
U.S. Senate
3rd Quarter, 2016
In Q3, Roberti Global (fka Roberti White, LLC) lobbied for Pfizer Inc. , earning $80,000. The report was filed on Oct. 20, 2016.
Original Filing: 300837976.xml
Lobbying Issues
- Issue on international trade
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
- Issues related to international tax reform and inversions
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
- Medicare Rebates
- Medicare Part D
- CMMI Part B Drug Price Demonstration Program
- Non-Interference
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Prescription opioid-related issues
- Federal, Food, Drug, and Cosmetic Act
- Patient Protection and Affordable Care Act implementation
- 21st Century Cures Act (H.R. 6)
- Innovation for Healthier Americans (Senate)
- Part B drug payment demonstration rule
Agencies Lobbied
U.S. Senate
2nd Quarter, 2016
In Q2, Roberti Global (fka Roberti White, LLC) lobbied for Pfizer Inc. , earning $80,000. The report was filed on July 20, 2016.
Original Filing: 300820676.xml
Lobbying Issues
Issues on international trade
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to international tax reform and inversions
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Medicare Rebates
Medicare Part D
Non-Interference
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Prescription opioid-related issues
- Federal, Food, Drug and Cosmetic Act
- Patient Protection and Affordable Care Act implementation
- 21st Century Cures Act (H.R. 6)
- Innovation for Healthier Americans (Senate)
- Part B drug payment demonstration rule
Agencies Lobbied
U.S. Senate
1st Quarter, 2016
In Q1, Roberti Global (fka Roberti White, LLC) lobbied for Pfizer Inc. , earning $80,000. The report was filed on April 20, 2016.
Original Filing: 300803089.xml
Lobbying Issues
Issues on international trade
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to international tax reform and inversions
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Medicare Rebates
Medicare Part D
Non-Interference
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Prescription opioid-related issues
- Federal, Food, Drug and Cosmetic Act
- Patient Protection and Affordable Care Act implementation
- 21st Century Cures Act (H.R. 6)
- Innovation for Healthier Americans (Senate)
- Part B drug payment demonstration rule
Agencies Lobbied
U.S. Senate
4th Quarter, 2015
Roberti Global (fka Roberti White, LLC) amended a lobbying report for representation of Pfizer Inc. in Q42015 on Jan. 21, 2016.
Original Filing: 300784684.xml
Lobbying Issues
Issues on international trade
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to international tax reform and inversions
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Medicare Rebates
Medicare Part D
Non-Interference
Agencies Lobbied
U.S. Senate
Lobbying Issues
Prescription opioid-related issues
Federal, Food, Drug and Cosmetic Act
Patient Protection and Affordable Care Act implementation
Agencies Lobbied
U.S. Senate
4th Quarter, 2015
In Q4, Roberti Global (fka Roberti White, LLC) lobbied for Pfizer Inc. , earning $80,000. The report was filed on Jan. 20, 2016.
Original Filing: 300784412.xml
Lobbying Issues
Issues on international trade
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to tax reform
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Medicare Rebates
Medicare Part D
Non-Interference
Agencies Lobbied
U.S. Senate
Lobbying Issues
Prescription opioid-related issues
Federal, Food, Drug and Cosmetic Act
Patient Protection and Affordable Care Act implementation
Agencies Lobbied
U.S. Senate
3rd Quarter, 2015
In Q3, Roberti White, LLC lobbied for Pfizer Inc. , earning $80,000. The report was filed on Oct. 20, 2015.
Original Filing: 300761375.xml
Lobbying Issues
Issues on international trade
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to tax reform
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Medicare Rebates
Medicare Part D
Non-Interference
Agencies Lobbied
U.S. Senate
Lobbying Issues
Prescription opioid-related issues
Federal, Food, Drug and Cosmetic Act
Patient Protection and Affordable Care Act implementation
Agencies Lobbied
U.S. Senate
2nd Quarter, 2015
In Q2, Roberti White, LLC lobbied for Pfizer Inc. , earning $80,000. The report was filed on July 20, 2015.
Original Filing: 300743914.xml
Lobbying Issues
Issues on international trade
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to tax reform
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Medicare Rebates
Medicare Part D
Non-Interference
Agencies Lobbied
U.S. Senate
Lobbying Issues
Prescription opioid-related issues
Federal, Food, Drug and Cosmetic Act
Patient Protection and Affordable Care Act implementation
Agencies Lobbied
U.S. Senate
1st Quarter, 2015
In Q1, Roberti White, LLC lobbied for Pfizer Inc. , earning $80,000. The report was filed on April 20, 2015.
Original Filing: 300723190.xml
Lobbying Issues
Issues on international trade
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to tax reform
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Medicare Rebates
Medicare Part D
Non-Interference
SGR
Agencies Lobbied
U.S. Senate
Lobbying Issues
Prescription opioid-related issues
Federal, Food, Drug and Cosmetic Act
Patient Protection and Affordable Care Act implementation
Agencies Lobbied
U.S. Senate
4th Quarter, 2014
In Q4, Roberti White, LLC lobbied for Pfizer Inc. , earning $70,000. The report was filed on Jan. 20, 2015.
Original Filing: 300704622.xml
Lobbying Issues
Issues on international trade
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to tax reform
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Medicare Rebates
Medicare Part D
Non-Interference
SGR
Agencies Lobbied
U.S. Senate
Lobbying Issues
Prescription opioid-related issues
Federal, Food, Drug and Cosmetic Act
Patient Protection and Affordable Care Act implementation
Agencies Lobbied
U.S. Senate
3rd Quarter, 2014
In Q3, Roberti White, LLC lobbied for Pfizer Inc. , earning $80,000. The report was filed on Oct. 19, 2014.
Original Filing: 300682544.xml
Lobbying Issues
Issues on international trade
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to tax reform
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Medicare Rebates; Medicare Part D; Non-Interference; SGR
Agencies Lobbied
U.S. Senate
Lobbying Issues
Prescription opioid-related issues; Federal, Food, Drug and Cosmetic Act; Patient Protection and Affordable Care Act implementation
Agencies Lobbied
U.S. Senate
2nd Quarter, 2014
In Q2, Roberti White, LLC lobbied for Pfizer Inc. , earning $70,000. The report was filed on July 22, 2014.
Original Filing: 300670036.xml
Lobbying Issues
Issues on international trade
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to tax reform
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Medicare Rebates; Medicare Part D; Non-Interference; SGR
Agencies Lobbied
U.S. Senate
Lobbying Issues
Prescription opioid-related issues; Federal, Food, Drug and Cosmetic Act; Patient Protection and Affordable Care Act implementation
Agencies Lobbied
U.S. Senate
1st Quarter, 2014
In Q1, Roberti White, LLC did no lobbying for Pfizer Inc. . The report was filed on April 22, 2014.
Original Filing: 300649506.xml
1st Quarter, 2014
Roberti White, LLC filed a lobbying registration on April 21, 2014 to represent Pfizer Inc., effective Jan. 31, 2014.
Original Filing: 300649067.xml
Issue(s) they said they’d lobby about: Issues on international trade, healthcare, and medicare/medicaid. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...